Aadi Bioscience, founded with the mission to improve the lives of people with mTOR-driven diseases, focuses on developing precision therapies for genetically-defined cancers. Utilizing advanced genomic profiling technology and albumin-bound nanoparticle technology, Aadi aims to overcome the limitations of current mTOR inhibitors. Their market focus is on patients in the United States who are most likely to benefit from these targeted therapies.
Notable affiliates include a team of experienced biopharmaceutical professionals and investors committed to advancing cancer treatment. Key achievements include progressing through clinical stages and demonstrating the potential of their precision medicine approach. Aadi Bioscience's impact lies in its innovative approach to treating genetic cancers, offering hope for more effective and personalized cancer therapies.
Aadi Bioscience
- Company Overview
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Biotech
Aadi Bioscience
- Operating Model
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
Aadi Bioscience - FAQ
When was Aadi Bioscience founded?
Aadi Bioscience was founded in 2011.
Where is Aadi Bioscience's headquarters located?
Aadi Bioscience's headquarters is located in Pacific Grove, CA, US.
When was Aadi Bioscience's last funding round?
Aadi Bioscience's most recent funding round was for $72.5M (USD) in September 2022.
How many employees does Aadi Bioscience have?
Aadi Bioscience has 83 employees as of Feb 6, 2024.
How much has Aadi Bioscience raised to-date?
As of July 05, 2023, Aadi Bioscience has raised a total of $250.5M (USD) since Sep 22, 2022.
Aadi Bioscience - Comparables
Add Comparison
Aadi Bioscience - Fundraising
Total Raised to Date
$250.5M
USD
Last Update Sep 22, 2022
Last Deal Details
$72.5M
USD
Sep 22, 2022
Post Ipo Equity
Aadi Bioscience - Employees
Total Employees Over Time
83
As of Feb 2024
Aadi Bioscience - Contact Information
Aadi Bioscience Address
17383 Sunset Blvd
Suite A250
Pacific Grove,
California
90272
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.